Oramed Pharmaceuticals (ORMP) Projected to Post Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) is anticipated to announce its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Oramed Pharmaceuticals Stock Performance

NASDAQ ORMP opened at $3.42 on Wednesday. The stock has a fifty day moving average of $3.42 and a 200-day moving average of $2.90. The stock has a market capitalization of $136.12 million, a P/E ratio of 2.71 and a beta of 1.31. Oramed Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $3.76.

Oramed Pharmaceuticals Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, January 26th. Shareholders of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is presently 19.84%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Oramed Pharmaceuticals presently has an average rating of “Hold”.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several institutional investors have recently modified their holdings of ORMP. Jane Street Group LLC lifted its holdings in shares of Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 17,510 shares in the last quarter. Bank of America Corp DE increased its stake in Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after purchasing an additional 6,261 shares in the last quarter. HRT Financial LP acquired a new stake in Oramed Pharmaceuticals during the 4th quarter worth approximately $131,000. Marshall Wace LLP acquired a new stake in Oramed Pharmaceuticals during the 4th quarter worth approximately $738,000. Finally, Squarepoint Ops LLC lifted its stake in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 28,406 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.